AbbVie Inc vs Bank of New York Mellon Corp — how do they compare? AbbVie Inc trades at $250.35 (market cap $438.19B), while Bank of New York Mellon Corp trades at $161 (market cap $108.17B). The key difference: AbbVie Inc is far larger — about 4.1× Bank of New York Mellon Corp's market cap, and AbbVie Inc pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| ABBV | BNY | |
|---|---|---|
Market Cap | $438.19B | $108.17B |
Sector | Health | Financials |
52-Week High | $263.58 | $162.35 |
52-Week Low | $197.38 | $101.00 |
Enterprise Value | $502.45B | — |
Dividend Yield | 2.79% | 1.39% |
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.
Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.
BNY trades at $157.65, down 0.75% on the day, with a bullish technical signal from moving averages but neutral oscillators. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.46 exceeding expectations. Revenue and net income have shown steady growth, with 2025 revenue at $19.76 billion and net income at $5.55 billion. Recent news highlights BNY's expansion into digital transfer agency capabilities and a strategic collaboration with Galaxy Digital to advance digital asset infrastructure, signaling innovation in fund servicing.
The outlook for BNY is positive, supported by strong earnings performance, a consensus price target of $170.36, and a bullish analyst rating upgrade to Strong Buy by Zacks. Investment opportunities include continued revenue growth and margin expansion. Risks involve high investing cash outflows, competitive pressures in custody banking, and sensitivity to interest rate changes. The stock offers a dividend yield with recent increases, appealing to income-focused investors amid solid fundamentals.
Trailing returns across standard periods
Latest headlines on both assets
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.
Read more on BNY →